You are here

Company Monitoring Page for Incyte

latest headlines for company on cafepharma

In a surprise approval, FDA green-lights Incyte's PD-1 inhibitor to treat rare cancer type

Fierce Pharma

Wed, 03/22/23 - 09:27 pm

Tags:

Incyte, Zynyz, FDA, Merkel cell carcinoma

Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose

Endpoints

Tue, 03/21/23 - 10:06 am

Tags:

AAD, Incyte, JAK inhibitors, povorcitinib, vitiligo

Incyte reports data from Phase IIb vitiligo therapy trial

Clinical Trials Arena

Mon, 03/20/23 - 11:27 am

Tags:

Incyte, povorcitinib, vitiligo, clinical trials

Incyte Abandons Phase III Trial for Myelofibrosis Treatment

BioSpace

Mon, 03/6/23 - 11:06 am

Tags:

Incyte, clinical trials, myelofibrosis, Jakafi

Go or no go? Vaccines and neurology up for discussion

EP Vantage

Tue, 02/28/23 - 11:05 am

Incyte reports new data from hidradenitis suppurativa therapy trial

Clinical Trials Arena

Mon, 02/13/23 - 10:25 am

Tags:

Incyte, clinical trials, hidradenitis suppurativa, povorcitinib

Insmed, Alnylam and others make Science's list of top 20 biopharma employers

Endpoints

Sun, 11/6/22 - 01:32 pm

Tags:

employers, Inbsmed, Alnylam, Regeneron, Incyte

SITC 2022 preview – cytokines and oral checkpoints

EP Vantage

Thu, 10/6/22 - 10:39 am

Tags:

SITC, Incyte, ChemoCentryx, Amgen, cytokines

Incyte pays out $70M to get hands on Medicxi-backed vitiligo biotech

Endpoints

Mon, 10/3/22 - 10:21 am

Tags:

Incyte, M&A, Villaris Therapeutics, vitiligo, Medicxi

FDA Action Alert: Incyte, Arcutis Await Decisions in Vitiligo, Psoriasis

BioSpace

Mon, 07/18/22 - 10:22 am

Tags:

FDA, Incyte, Arcutis Biotherapeutics, Opzelura, vitiligo, roflumilast, psoriasis

MorphoSys Adds HIBio to Busy Collaboration Week

BioSpace

Wed, 06/15/22 - 11:03 am

Tags:

MorphoSys, HIBio, Pfizer, Incyte

Opportunities arise for once-spurned partners

EP Vantage

Fri, 05/13/22 - 10:34 am

FDA approves new indication for drug to treat severe COVID-19

Beckers Hospital Review

Thu, 05/12/22 - 10:51 pm

Tags:

Eli Lilly, Incyte, baricitinib, FDA, olumiant, COVID-19

Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch

Fierce Pharma

Mon, 03/14/22 - 11:37 pm

Tags:

Incyte, Opzelura, eczema, vitiligo

A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers

Endpoints

Tue, 03/1/22 - 10:35 am

Tags:

CTI BioPharma, JAK inhibitors, Vonjo, pacritinib, FDA, myelofibrosis, Incyte, Bristol Myers Squibb

Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data

Fierce Biotech

Wed, 02/2/22 - 10:59 am

Tags:

Novartis, Incyte, JAK inhibitors, Opzelua, eczema, atopic dermatitis

Eli Lilly, Incyte axe Olumiant in lupus amid eczema stalemate at FDA

Fierce Pharma

Fri, 01/28/22 - 11:47 am

Tags:

Eli Lilly, Incyte, olumiant, FDA, lupus, eczema

Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit

Fierce Biotech

Wed, 01/26/22 - 10:57 am

Tags:

Incyte, FDA, parsaclisib

FDA sets April date for verdict on Incyte’s vitiligo drug

Pharmaforum

Wed, 12/15/21 - 10:43 am

Tags:

Incyte, Opzelura, vitiligo, FDA

What Novartis could buy with its windfall

EP Vantage

Fri, 11/5/21 - 09:40 am

Tags:

Novartis, M&A, Roche, Sandoz, Aurinia Pharmaceuticals, Alnylam, Exelixis, Incyte, Eisai, Genmab

Pages

last 30 twitter posts